在急性髓系白血病中拓展达沙替尼超出KIT靶点的应用范围。 - Suppr

Suppr

超能文献

Expanding dasatinib beyond KIT in acute myeloid leukemia.

作者信息

Welch John S

机构信息

Washington University School of Medicine, St. Louis, MO, USA.

出版信息

Haematologica. 2020 Dec 1;105(12):2708-2710. doi: 10.3324/haematol.2020.262147.

DOI:10.3324/haematol.2020.262147

PMID:33256372

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7716351/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d20f/7716351/ee74d4c59b6f/1052708.fig1.jpg

相似文献

Expanding dasatinib beyond KIT in acute myeloid leukemia.在急性髓系白血病中拓展达沙替尼超出KIT靶点的应用范围。

Haematologica. 2020 Dec 1;105(12):2708-2710. doi: 10.3324/haematol.2020.262147.

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.达沙替尼用于首次完全缓解的高危核心结合因子急性髓系白血病：一项法国急性髓系白血病协作组试验

Haematologica. 2015 Jun;100(6):780-5. doi: 10.3324/haematol.2014.114884. Epub 2015 Feb 24.

Inhibition of c-Kit by tyrosine kinase inhibitors.酪氨酸激酶抑制剂对c-Kit的抑制作用。

Haematologica. 2015 Mar;100(3):e77-9. doi: 10.3324/haematol.2014.117028. Epub 2014 Nov 25.

Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.KIT(mut) t(8;21) 急性髓系白血病细胞中的瞬时达沙替尼耐药状态与 KIT 表达改变相关。

Exp Hematol. 2014 Feb;42(2):90-100. doi: 10.1016/j.exphem.2013.10.006. Epub 2013 Nov 6.

Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.鉴定一种用于治疗胃肠道间质瘤和急性髓系白血病的多靶点酪氨酸激酶抑制剂。

J Med Chem. 2019 Dec 26;62(24):11135-11150. doi: 10.1021/acs.jmedchem.9b01229. Epub 2019 Dec 6.

Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.达沙替尼治疗的慢性髓性白血病在费城阴性细胞中迅速发展为伴有7号染色体单体的急性髓性白血病的基因分析。

Cancer Genet Cytogenet. 2010 Jun;199(2):89-95. doi: 10.1016/j.cancergencyto.2010.02.005.

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.化疗和达沙替尼可使伴有KIT D816V的系统性肥大细胞增多症合并急性髓系白血病获得长期血液学和分子学缓解。

Leuk Res. 2009 May;33(5):735-41. doi: 10.1016/j.leukres.2008.09.027. Epub 2008 Nov 4.

[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].[使用酪氨酸激酶抑制剂治疗c-KIT突变与AML1-ETO双阳性难治性急性髓系白血病]

Rinsho Ketsueki. 2012 Apr;53(4):460-4.

Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.治疗急性髓系白血病的现有及新兴治疗选择。

Clin Adv Hematol Oncol. 2008 Nov;6(11):3-5.

Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes.检测不同亚型急性髓系白血病中的 KIT 和 FLT3 突变。

Arch Iran Med. 2010 Jan;13(1):21-5.

引用本文的文献

The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View.急性髓系白血病的免疫治疗：临床视角

Cancers (Basel). 2024 Jun 27;16(13):2359. doi: 10.3390/cancers16132359.

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.急性髓系白血病中突变型 KIT 酪氨酸激酶作为一个新的分子靶点。

Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694.

The Multi-Omic Prognostic Model of Oxidative Stress-Related Genes in Acute Myeloid Leukemia.急性髓系白血病中氧化应激相关基因的多组学预后模型

Front Genet. 2021 Sep 30;12:722064. doi: 10.3389/fgene.2021.722064. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验